Compare OXM & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OXM | CSTL |
|---|---|---|
| Founded | 1942 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.3M | 597.8M |
| IPO Year | 1994 | 2019 |
| Metric | OXM | CSTL |
|---|---|---|
| Price | $45.32 | $21.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $38.00 | ★ $45.50 |
| AVG Volume (30 Days) | 245.2K | ★ 491.9K |
| Earning Date | 06-10-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,477,834,000.00 | $344,229,000.00 |
| Revenue This Year | $2.85 | $2.42 |
| Revenue Next Year | $2.63 | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $30.57 | $14.59 |
| 52 Week High | $56.34 | $44.28 |
| Indicator | OXM | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 51.58 |
| Support Level | $35.94 | $17.72 |
| Resistance Level | $48.02 | $22.18 |
| Average True Range (ATR) | 2.23 | 1.11 |
| MACD | 0.36 | 0.31 |
| Stochastic Oscillator | 61.85 | 85.95 |
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company's business is organized as: Tommy Bahama, Lilly Pulitzer, Johnny Was and Emerging Brands reportable segments. Geographically, the company operates in United States as well as Internationally.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.